Stocks Getting Their Groove Back: Realogy Holdings Corp. (RLGY), Abbott Laboratories (ABT) – The RNS Daily

This post was originally published on this site

Realogy Holdings Corp. (NYSE:RLGY) rose 5.71% this week, a trend that has led to both investors and traders taking note of the stock. Over the past one year, the equity price has embarked on a drop that has seen it decline -50.98% and is now down by -12.94% since start of this year. A look at its monthly performance shows that the stock has recorded a 9.14% gain over the past 30 days. Its equity price dipped by -28.4% over the past three months which led to its overall six-month decrease to stand at -30.88%.

The shares of Realogy Holdings Corp. (RLGY) dropped by -53.36% or -$14.62 from its last recorded high of $27.4 which it attained on April 18 to close at $12.78 per share. Over the past 52 weeks, the shares of Realogy Holdings Corp. has been trading as low as $10.92 before witnessing a massive surge by 17.03% or $1.86. This price movement has led to the RLGY stock receiving more attention and has become one to watch out for. It dipped by -1.31% on Monday and this got the market worried. The stock’s beta now stands at 1.34 and when compared to its 200-day moving average and its 50-day moving average, RLGY price stands -29.95% below and -9.02% below respectively. Its average daily volatility for this week is 2.61% which is less than the 3.55% recorded over the past month.

Experts from research firms are bullish about the near-term performance of Realogy Holdings Corp. with most of them predicting a $14.61 price target on a short-term (12 months) basis. The average price target by the analysts will see a 14.32% rise in the stock and would lead to RLGY’s market cap to surge to $1.7B. The stock has been rated an average 3.2, which roughly stands towards the bearish end of the spectrum. Reuters looked into the 8 analysts that track Realogy Holdings Corp. (NYSE:RLGY) and find out that 5 of them rated it as a Hold. 1 of the 3 analysts rated it as a Buy or a Strong Buy while 2 advised investors to desist from buying the stock or sell it if they already possess it.

A look at RLGY technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 49.13 point. Its trading volume has lost -1018764 shares compared to readings over the past three months as it recently exchanged 1441236 shares. This means there is reduced activity from short-term traders as per session, its average trading volume is 2460000 shares, and this is 0.59 times the normal volume.

The price of Abbott Laboratories (NYSE:ABT) currently stands at $77.5 after it went down by $-0.51 or -0.65% and has found a strong support at $77.15 a share. If the ABT price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $76.81 mark would also be bad for the stock as it means that the stock would plunge by 0.89% from its current position. However, if the stock price is able to trade above the resistance point around $78.15, then it could likely surge higher to try and break the upward resistance which stands at $78.8 a share. Its average daily volatility over the past one month stands at 1.48%. The stock has plunged by 0.05% from its 52-weeks high of $77.46 which it reached on Jan. 04, 2019. In general, it is 26.7% above its 52-weeks lowest point which stands at $56.81 and this setback was observed on Mar. 05, 2018.

Analysts have predicted a price target for Abbott Laboratories (ABT) for 1 year and it stands at an average $82.78/share. This means that it would likely increase by 6.81% from its current position. The current price of the stock has been moving between $77.46 and $78.455. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $76. On the other hand, one analyst is super bullish about the price, setting a target as high as $88.

The ABT stock Stochastic Oscillator (%D) is at 19.79%, which means that it is currently oversold and its prices could jump very soon. The shares P/S ratio stands at 4.43 which compares to the 6.68 recorded by the industry or the 8.39 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 21.55, which is lower than the 55.68 multiple of 12-month price-earnings (P/E). The company’s earnings have gone up, with a quarterly increase rate of 2% over the past five years.

Analysts view Abbott Laboratories (NYSE:ABT) as a Buy, with 1.9 consensus rating. Reuters surveyed 21 analysts that follow ABT and found that 2 of those analysts rated the stock as a Hold. The remaining 19 were divided, with 18 analyst rating it as a Buy or a Strong Buy while 1 analysts advised investors to desist from buying Abbott Laboratories (ABT) shares or sell it if they already own it.

This post was originally published on *this site*